摘要
目的 探讨度拉糖肽配合胰岛素在初诊肥胖的2型糖尿病患者中的应用效果。方法 选取福建省连江县医院2021年8月—2022年3月期间收治的60例初诊肥胖的2型糖尿病患者作为研究对象,分为观察组(度拉糖肽配合胰岛素强化治疗)和对照组(胰岛素强化治疗)各30例,比较两组患者的治疗效果。结果 观察组患者治疗后的空腹血糖(FPG)水平(7.05±0.85)mmol/L、餐后2 h血糖(2 hPG)水平(8.86±1.29)mmol/L低于对照组,差异有统计学意义(t=3.548、2.145,P<0.05)。观察组患者的体质指数(BMI)水平(25.43±1.18)kg/m2、内脏脂肪厚度(26.21±1.24)mm低于对照组,差异有统计学意义(t=2.225、3.765,P<0.05)。结论 在初诊肥胖的2型糖尿病患者的临床治疗中,采用度拉糖肽配合胰岛素治疗方法,可以有效改善糖脂代谢,获得良好的治疗效果。
Objective To investigate the application effect of dulaglutide combined with insulin in newly diagnosed obese patients with type 2 diabetes.Methods A total of 60 newly diagnosed obese patients with type 2 diabetes who were admitted to Lianjiang County Hospital in Fujian Province from August 2021 to March 2022 were selected as the research subjects and divided into observation group(dulaglutide combined with intensive insulin therapy) and control group(intensive insulin therapy) with 30 cases in each group.The therapeutic effects of the two groups of patients were compared.Results The fasting blood glucose(FPG) level(7.05±0.85) mmol/L and 2 h postprandial blood glucose(2 hPG) level(8.86±1.29) mmol/L in the observation group after treatment were lower than those in the control group,the difference was statistically significant(t=3.548,2.145,P<0.05).The body mass index(BMI) level(25.43±1.18) kg/m2and visceral fat thickness(26.21±1.24) mm of the observation group were lower than those of the control group,the difference was statistically significant(t=2.225,3.765,P<0.05).Conclusion In the clinical treatment of newly diagnosed obese patients with type 2 diabetes,the use of dulaglutide combined with insulin therapy can effectively improve glucose and lipid metabolism and achieve good therapeutic effects.
作者
严颖
YAN Ying(Department of Internal Medicine,Lianjiang County Hospital,Fuzhou,Fujian Province,350500 China)
出处
《糖尿病新世界》
2022年第17期79-82,共4页
Diabetes New World Magazine
关键词
肥胖
2型糖尿病
度拉糖肽
胰岛素
糖脂代谢强化治疗
Obesity
Type 2 diabetes
Dulaglutide
Insulin
Intensive treatment of glucose and lipid metabolism
